Anti-irritant Emulsion Formulations for IV Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery methods face challenges in solubilizing hydrophobic or amphiphilic drugs for intravenous administration, leading to issues like precipitation, pain, inflammation, hemolysis, and phlebitis, especially when conventional solubilization techniques are insufficient.
Innovation Solution
The development of anti-irritant emulsion formulations comprising an oil phase with a hydrophobic or amphiphilic irritant agent, a phospholipid emulsifier, and an aqueous phase with a charge stabilizer, which are stable and provide a protective effect against irritation, using specific buffers and phospholipids like egg lecithin to maintain pH and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydrophobic or amphiphilic drugs are administered intravenously using conventional solubilization techniques, then the drugs can be delivered to therapeutic targets, but precipitation, pain, inflammation, hemolysis, and phlebitis occur
Solution Approach 1:
The patent introduces a multi-component emulsion system consisting of phospholipids, surfactants, and co-solvents as intermediary substances. These components work together to solubilize hydrophobic drugs in aqueous injection vehicles, preventing direct contact between the hydrophobic drug and biological tissues that would cause irritation. The emulsion formulation acts as a mediator that maintains drug solubility while eliminating harmful effects.
Solution Approach 2:
The invention employs composite emulsion formulations combining multiple solubilization mechanisms: phospholipid vesicles, surfactant micelles, and co-solvent systems. This composite approach integrates different materials (phospholipids, surfactants, co-solvents) to achieve superior drug solubilization and stability compared to single-component systems, thereby preventing precipitation and tissue irritation.
2Quantity of substance
If pH adjustment is used to solubilize ionizable drugs, then the desired concentration can be achieved, but the buffer concentration must be high enough to maintain pH, which may cause in vivo tolerability issues
Solution Approach 1:
The patent combines multiple solubilization techniques into a single integrated formulation system. By merging phospholipid emulsification, surfactant micelle formation, and co-solvent solubilization, the system achieves high drug concentration solubilization without relying on high buffer concentrations. This combination approach allows pH adjustment to be used at lower, more tolerable concentrations while maintaining drug solubility through the synergistic action of multiple components.
3Quantity of substance
If surfactants like Cremophor EL or polysorbate 80 are used to solubilize water-insoluble drugs, then solubility is improved, but precipitation, pain, inflammation, hemolysis, and phlebitis may still occur
Solution Approach 1:
The patent creates a multi-functional formulation system where phospholipids, surfactants, and co-solvents perform multiple functions simultaneously. The phospholipids provide emulsification and vesicle formation, surfactants provide micellar solubilization and surface activity, and co-solvents provide molecular-level solubilization. This multi-functionality ensures comprehensive drug solubilization while the collective action of all components prevents the harmful effects associated with single surfactant systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These formulations effectively reduce or eliminate precipitation, pain, inflammation, and hemolysis, ensuring the stability and safety of the drug delivery, allowing for effective intravenous administration of challenging drugs.
Implementation Method 1
phospholipid emulsifier
Implementation Method 2
aqueous phase containing a charge stabilizer, wherein the stabilizer has pHpKa of the irritant agent
Data Source
AI summary
The present invention relates to injectable formulations of irritant agents, such as calcimimetics, that are pharmaceutically stable and demonstrate a reduced incidence of irritation, pain, phlebitis, precipitation and hemolysis upon injection.